Roth Capital Expects Weaker Earnings for Tenax Therapeutics

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at Roth Capital reduced their FY2027 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a report released on Wednesday, March 5th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings of $1.74 per share for the year, down from their prior forecast of $1.82. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ FY2028 earnings at $2.94 EPS.

Tenax Therapeutics Stock Performance

TENX stock opened at $6.19 on Friday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The business has a 50-day moving average price of $6.45 and a 200 day moving average price of $5.16.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TENX. Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics during the third quarter valued at approximately $288,000. Sphera Funds Management LTD. purchased a new stake in Tenax Therapeutics during the third quarter worth $101,000. Stonepine Capital Management LLC bought a new stake in Tenax Therapeutics during the 3rd quarter valued at $173,000. Two Sigma Investments LP purchased a new position in shares of Tenax Therapeutics in the 4th quarter valued at $84,000. Finally, Millennium Management LLC purchased a new position in shares of Tenax Therapeutics in the 4th quarter valued at $166,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.